OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research report report published on Saturday morning. The firm issued a sell rating on the stock.

OCX has been the topic of a number of other research reports. Benchmark reiterated a speculative buy rating and set a $5.00 price target on shares of OncoCyte in a research report on Monday, April 15th. Stephens reiterated an equal weight rating and set a $4.00 price target on shares of OncoCyte in a research report on Wednesday, April 17th. Finally, Needham & Company LLC reiterated a buy rating and set a $4.25 price target on shares of OncoCyte in a research report on Thursday, May 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus price target of $4.06.

OncoCyte Stock Performance

Shares of OCX opened at $2.95 on Friday. OncoCyte has a 52 week low of $2.08 and a 52 week high of $4.86. The stock’s 50-day moving average price is $2.74 and its 200-day moving average price is $2.90.

OncoCyte (NASDAQ:OCX) last issued its earnings results on Wednesday, May 15th. The company reported ($1.13) EPS for the quarter. OncoCyte had a negative return on equity of 135.45% and a negative net margin of 2,905.14%. The company had revenue of $0.18 million during the quarter. Research analysts predict that OncoCyte will post -2.58 EPS for the current fiscal year.

Insider Activity

In other news, Director Andrew Arno bought 33,898 shares of the firm’s stock in a transaction dated Thursday, April 11th. The shares were acquired at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the completion of the transaction, the director now directly owns 69,054 shares in the company, valued at approximately $203,709.30. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Andrew Arno purchased 33,898 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average price of $2.95 per share, with a total value of $99,999.10. Following the completion of the acquisition, the director now owns 69,054 shares in the company, valued at $203,709.30. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was bought at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the acquisition, the insider now owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The disclosure for this purchase can be found here. Insiders have bought a total of 2,457,288 shares of company stock worth $7,176,400 over the last quarter. 1.94% of the stock is currently owned by corporate insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.